statnews.com·May 11, 2026
The FDA is facing potential leadership changes with questions about Commissioner Marty Makary's future, while there are developments in a revived gene therapy for a rare disease and disappointing adoption rates for Alzheimer's drugs.
The current unrest at the FDA, especially concerning Commissioner Marty Makary's potential ousting, could impact the regulatory landscape for healthtech and biotech innovations. Monitoring these developments is crucial, as leadership changes may influence the approval process for emerging technologies and treatments.